Contineum Therapeutics (Contineum Therapeutics) EV-to-EBITDA : -18.28 (As of May. 25, 2024)

Contineum Therapeutics EV-to-EBITDA Chart

Competitive Comparison of Contineum Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Contineum Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's EV-to-EBITDA falls into.

Contineum Therapeutics EV-to-EBITDA Calculation

Contineum Therapeutics's EV-to-EBITDA for today is calculated as:

Contineum Therapeutics's current Enterprise Value is $297.08 Mil.
Contineum Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics  (NAS:CTNM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Contineum Therapeutics's PE Ratio for today is calculated as:

Contineum Therapeutics's share price for today is $15.76.
Contineum Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.598.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Contineum Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description